Screener
AngioDynamics ANGO Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: AngioDynamics’s 10-Q, filed April 2, 2026.
- Filed
- Apr 2, 2026, 12:00 AM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-023008
| Line item | Nine Months Ended / Feb 28, 2026 | Nine Months Ended / Feb 28, 2025 |
|---|---|---|
| Proceeds from exercise of stock options and employee stock purchase plan | 950 | 933 |
| Net cash provided by financing activities | 672 | 5,515 |
| Effect of exchange rate changes on cash | 287 | (317) |
| Decrease in cash | (18,083) | (31,296) |
| Cash at beginning of period | 55,893 | 76,056 |
| Cash at end of period | $37,810 | $44,760 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Accrual for capital expenditures incurred during the period | $(15) | $7 |
Item 1. Financial Statements.
FAQ
- What is AngioDynamics's net change in cash?
- AngioDynamics (ANGO) reported net change in cash of -$3.83M in Q4 2025.
- How has AngioDynamics's net change in cash changed year-over-year?
- AngioDynamics's net change in cash increased by 59.0% year-over-year, from -$9.33M to -$3.83M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about AngioDynamics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude